|Bid||25.97 x 1200|
|Ask||25.98 x 1000|
|Day's Range||25.90 - 26.05|
|52 Week Range||11.03 - 26.57|
|Beta (5Y Monthly)||1.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.70|
Zogenix (NASDAQ: ZGNX) stock is having the ride of its life this week -- perhaps for the last time in its history. The biotech announced Wednesday it agreed to be acquired by Belgium-based pharmaceutical company UCB (OTC: UCBJF). The company's share price quickly rocketed higher, but it's basically stayed at the enhanced level.
Regulatory and other pipeline updates from Zogenix (ZGNX) and Regeneron (REGN) are among a few key highlights from the biotech sector during the past week.
Belgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022.